Accordingly, LANCL2 was, so far, investigated as a promising target for chronic inflammatory, metabolic, and immune-mediated diseases, such as inflammatory bowel disease (IBD), and cancer [21,22]. Here, LANCL2 is linked to inflammatory bowel disease.